To investigate the efficacy of Ex-press implantation combined with intravitreal leizumab injection and Ex-press implantation combined with mitomycin C in the treatment of complicated glaucoma.

The 26 cases of refractory glaucoma patients(30 eyes) were selected from January to August 2018.The patients were randomly divided into the leizumab group and mitomycin C group.Each group had 15 eyes(patients with binocular diseases were included in the same group). In the leizumab group, 4 males(5 eyes) and 8 females(10 eyes) were aged(58.6±8.7) years old, ranging from 45 to 76 years old.In mitomycin group C, 6 males(7 eyes) and 8 females(8 eyes) were aged(54.2±11.8) years old, ranging from 43 to 76 years old.Patients in the leizumab group received Ex-press implantation combined with intravitreal injection of leizumab, while patients in the mitomycin C group received Ex-press implantation combined with mitomycin C. The visual acuity, intraocular pressure and medication status of patients in the two groups were compared 1 day, 1 week, 1 month, 3 months and 6 months after surgery.

The visual acuity of the leizumab group was slightly higher at 1 day(0.44±0.09), 1 week(0.44±0.17), 1 month(0.43±0.07), 3 months(0.41±0.10) and 6 months(0.42±0.08) than that of the mitomycin C group[(0.36±0.11), (0.37±0.14), (0.35±0.08), (0.33±0.05) and(0.30±0.12)], with statistically significant differences(P<0.05). One day after surgery, the leizumab group[(12.15±3.52) mmHg, 1 mmHg=0.133 kPa] intraocular pressure at 1 week[(12.96±5.52) mmHg], 1 month[(13.32±3.74) mmHg], 3 months[(14.31±4.02) mmHg] and 6 months[(15.85±4.35) mmHg] was significantly lower than that in the mmHg group[(16.72±6.33)mmHg, (17.02±5.51)mmHg, (17.71±4.15)mmHg, (18.58±6.40)mmHg and(19.67±6.13)mmHg, with statistically significant differences(P<0.05). The types of lop drugs used in the leizumab group were less than those used in the mitomycin C group(0.42±0.37), (0.61±0.55) and(0.71±0.69) 1 month after surgery(0.33±0.29), 3 months(0.31±0.41) and 6 months(0.30±0.44), with statistically significant differences(P<0.05).

The efficacy of Ex-press implantation combined with intravitreal injection of tear-drop monoclonal antibody in the treatment of complicated glaucoma is better than Ex-press implantation combined with mitomycin C, which is worthy of clinical promotion and application.

Ex-press implantation; Ranibizumab; Mitomycin C; Refractory glaucoma